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Abstract
Background: An increase in non-B HIV-1 infections among men who have sex with men (MSM) in the United Kingdom (UK)
has created opportunities for novel recombinants to arise and become established. We used molecular mapping to
characterize the importance of such recombinants to the UK HIV epidemic, in order to gain insights into transmission
dynamics that can inform control strategies.
Methods and Results: A total of 55,556 pol (reverse transcriptase and protease) sequences in the UK HIV Drug Resistance
Database were analyzed using Subtype Classification Using Evolutionary Algorithms (SCUEAL). Overall 72 patients shared
the same A1/D recombination breakpoint in pol, comprising predominantly MSM but also heterosexuals and injecting drug
users (IDUs). In six MSM, full-length single genome amplification of plasma HIV-1 RNA was performed in order to
characterize the A1/D recombinant. Subtypes and recombination breakpoints were identified using sliding window and
jumping profile hidden markov model approaches. Global maximum likelihood trees of gag, pol and env genes were drawn
using FastTree version 2.1. Five of the six strains showed the same novel A1/D recombinant (8 breakpoints), which has been
classified as CRF50_A1D. The sixth strain showed a complex CRF50_A1D/B/U structure. Divergence dates and
phylogeographic inferences were determined using Bayesian Evolutionary Analysis using Sampling Trees (BEAST). This
estimated that CRF50_A1D emerged in the UK around 1992 in MSM, with subsequent transmissions to heterosexuals and
IDUs. Analysis of CRF50_A1D/B/U demonstrated that around the year 2000 CRF50_A1D underwent recombination with a
subtype B strain.
Conclusions: We report the identification of CRF50_A1D, a novel circulating recombinant that emerged in UK MSM around
1992, with subsequent onward transmission to heterosexuals and IDUs, and more recent recombination with subtype B.
These findings highlight the changing dynamics of HIV transmission in the UK and the converging of the two previously
distinct MSM and heterosexual epidemics.
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Introduction
The dynamics of the HIV epidemic are changing in the United
Kingdom (UK). By the end of 2010, approximately 91,500 people
were estimated to be living with HIV, including 40,100 men who
have sex with men (MSM), 47,000 heterosexual men and women
and 2,300 injecting drug users (IDUs) [1]. In previous years,
heterosexual infections, which were mostly imported, had over-
taken infections in MSM, 81% of which are indigenously
acquired. However, the trend has now reversed, reflecting a
decline in the number of infections acquired abroad, and a
corresponding increase in the number of infections acquired in the
UK [1]. These changes have considerable potential to modify
established epidemic patterns.
Mapping the molecular epidemiology of HIV infection can
provide valuable insights into transmission networks and thereby
inform prevention and containment strategies.
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As seen in other Western countries, including Italy and the
United States [2,3], in the UK the HIV epidemic among MSM
was traditionally composed of nearly uniformly subtype B
infections, contrasting with the variety of non-B subtypes found
in heterosexual infections, which are predominantly imported
from sub-Saharan Africa [4,5]. Non-B infections have been
increasing in recent years in MSM [2,6,7]. Under favorable
conditions such as those found in populations at risk of multiple
HIV exposures, novel recombinant strains can emerge and
become established, supplanting previous patterns of infection.
The emergence of recombinant HIV-1 strains among UK MSM
was proposed by Gifford et al. in 2007, based upon the detection of
a potentially novel subtype A recombinant in phylogenetic
analyses of pol gene sequences [6].
The aim of this study was to seek firmer evidence that novel
recombinant forms of HIV are emerging in the UK MSM
population. Through the screening of a large national database
containing reverse transcriptase and protease sequences from
patients undergoing drug resistance testing in routine care, and
subsequent near full-length, single genome sequencing (SGS) of
clinical isolates, we identified a novel A1/D circulating recombi-
nant form, now registered as CRF50_A1D, which first emerged in
the UK around 1992. We show that over time, CRF50_A1D
spread geographically and entered heterosexual and IDU trans-
mission networks, followed by recombination with a subtype B
strain and emergence of the unique recombinant form (URF)
CRF50/B/U. These findings indicate that the two previously
distinct HIV epidemics in MSM and heterosexuals have started to
converge in the UK, creating opportunities for greater HIV
genetic diversification.
Methods
Study population
The UK HIV Drug Resistance Database (HIV-DRD) (http://
www.hivrdb.org.uk/) and Public Health England (previously the
Health Protection Agency) provided access to pol sequences and
demographic and clinical data. The HIV-DRD is a national
repository of protease and reverse transcriptase sequences
obtained by Sanger sequencing in patients undergoing drug
resistance testing in routine care. At the time of the analysis, there
were 55,556 sequences in the database from both antiretroviral
treatment (ART)-naı¨ve and ART-experienced patients. Based
upon data from Gifford et al. indicating that a potentially novel
subtype A (sub-subtype A1) recombinant was circulating among
MSM in the UK [6], sequences from patients infected with sub-
subtype A1 were selected from the database for further analysis.
The REGA Subtyping tool and bootscanning analysis using
Simplot v3.5.1 were used to subtype recombinant sequences [8].
Subsequent subtyping was performed using Subtype Classification
Using Evolutionary Algorithms (SCUEAL) [9]. Stored plasma
samples from six selected patients were retrieved for further
sequence analysis.
Ethics statement
The Ethics Committee of the Royal Free Hospital in London
approved the anonymized use of stored plasma samples collected
during routine care. Personnel from the HIV-DRD selected
patients with different identifiers that attended centers with more
than 1000 patients in follow-up and were not known to be related,
and communicated the HIV-DRD identifier to the center of care
to allow sample retrieval from storage. Samples were anonymized
prior to shipment to the laboratory for sequencing.
Near full-length single genome sequencing
Near full-length SGS was performed using a protocol adapted
from the Centre for HIV/AIDS Vaccine Immunology (CHAVI-
MBSC 2009, unpublished) and optimised for plasma specimens
with low HIV-1 RNA levels. Briefly, 140 ml of plasma was adjusted
through either dilution or centrifugation to contain 20,000 HIV-1
RNA copies. RNA was extracted using the QiAmp Viral RNA
Mini kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions, with a final elution volume of 65 ml. All
extracted RNA was immediately transcribed with Superscript III
First Strand Synthesis Supermix (Life Technologies, Paisley, UK)
using the following protocol per reaction: 0.25 mM of reverse
primer 1.R3.B3R 59-ACTACTTGAAGCACTCAAGGCAAGC-
TTTATTG (CHAVI-MBSC 2009, unpublished), 1.87 ml nuclease
free water, 2.5 ml annealing buffer and 15 ml (5,000 copies) RNA
template were denatured at 65uC for 5 minutes. Reactions were
placed on ice for at least 1 minute before adding 25 ml of reaction
mixture and 5 ml of enzyme mixture. Reverse transcription was
performed at 50uC 90 minutes, 55uC 90 minutes, 85uC 5 min-
utes. An extra 2 ml of Superscript III RT Enzyme was added prior
to increasing the temperature to 55uC.
A two-step protocol was used to ensure single genome
amplification. The first step was a limiting dilution to assess that
cDNA was amplifying at rates suggesting near-ideal extraction and
reverse transcription conditions, i.e. that the undiluted cDNA
contained 100 copies/ml. Following this, cDNA was amplified
using a 1:200 cDNA dilution (a theoretical input of 1 copy/
reaction). In circumstances where the extracted number of HIV-1
RNA copies was below 20,000 copies, or the limiting dilution plate
suggested that the sample was amplifying suboptimally, dilutions
were adjusted accordingly.
Both first round and nested PCR reactions used the Platinum
PCR Supermix High Fidelity Kit (Life Technologies, Paisley, UK).
First round reactions comprised 45 ml PCR supermix, 0.25 mM
each forward primer 1.U5.B1F 59CCTTGAGTGCTTCAAG-
TAGTGTGTGCCCGTCTGT and reverse primer 1.R3.B3R,
0.5 ml nuclease free water and 2 ml cDNA. Cycling conditions
were 94uC 2 minutes, followed by 40 cycles of 94uC 15 s, 60uC
30 s, 68uC 9.5 m, and a final extension at 68uC 20 minutes.
Nested PCR reactions were identical to the first round reactions,
excepting the use of forward primer 2.U5.B4F 59-AG-
TAGTGTGTGCCCGTCTGTTGTGTGACTC, reverse primer
2.R3.B6R 59-TGAAGCACTCAAGGCAAGCTTTATTGAGGC,
and 45 cycles of PCR. The resulting 9 kb product spanned HXB2
nucleotides 552–9636.
Positive nested PCR reactions were identified using 1% agarose
gel electrophoresis. Filtered PCR products were directly sequenced
using fluorescently labeled dideoxy chain terminators (BigDye
Terminator v3.1 Cycle Sequencing Assay, Life Technologies) and
an automated ABI 37306l sequencer. Sequencing primers were
either sourced from the in-house protocols of the Molecular
Biology and Sequencing Core at the Centre for HIV/AIDS
Vaccine Immunology or protocols available in published literature
[10–12], or designed using Primer3 version 4.0 (http://frodo.wi.
mit.edu/primer3) (Supplementary information 1). Sequencing
reactions were repeated until near full bi-directional coverage
was obtained, and sequences were assembled using SeqScape
version 2.6 software (Life Technologies). Fragment sequences from
individual sequencing primers were examined for mixed bases;
where evidence of amplification of .1 target molecule was found,
amplification and sequencing was repeated.
Identification of HIV-1 CRF50_A1D
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Phylogenetic and recombination analyses
Recombination analyses and subtype assignation was performed
using the Recombinant Identification Program (RIP) (http://
www.hiv.lanl.gov/content/sequence/RIP/RIP.html), jpHMM
(http://jphmm.gobics.de) and Simplot [13]. For RIP and Simplot
analyses, a window size of 400 bp and a step size of 20 were used.
Sequences were gap-stripped and genetic distances were calculated
using Kimura 2-p parameters. Simplot analyses were performed
using a full-length reference alignment of 78 pure subtype
sequences. Bootscanning of the query sequence was performed
using subtypes A1, B, D, and F2 with informative sites analysis.
Recombination breakpoints were set using the highest statistically
significant X2 value around the 50% crossover point between
subtypes. The statistical significance of the identified breakpoints
was assessed using Fisher’s exact test. Following breakpoint
assignment, slices of the alignment corresponding to putative pure
subtype regions between each breakpoint were created and saved
for downstream analyses. Likelihood mapping of each slice was
used to assess phylogenetic signal prior to maximum likelihood
analysis and was performed using TreePuzzle [14].
Likelihood parameters for each putatively pure subtype region
of the HIV genome were estimated using PAUP version 4.0
(Sinauer Associates, Massachusetts, USA). Maximum likelihood
analysis was performed using the PhyML implementation housed
at the ATGC server (http://www.atgc-montpellier.fr/phyml/).
1000 bootstrapping replicates were performed, with the exception
of alignment slices 5 and 8, which were restricted to 100 replicates
to limit computational requirements.
Phylogenetic trees were visualized using Dendroscope version
2.3 (available from http://ab.inf.uni-tuebingen.de/data/software/
dendroscope3/download/welcome.html) and FigTree v1.3.1
(http://tree.bio.ed.ac.uk/software/figtree/). Schematics of final-
ized recombinant structures were drawn using the Recombinant
HIV-1 Drawing Tool (RDT), available from the Los Alamos
website (http://www.hiv.lanl.gov/content/sequence/DRAW_CRF/
recom_mapper.html).
Beyond full-length sequencing, further instances of
CRF50_A1D infections were identified using BLAST to compare
three representative CRF50_A1D sequences (33365, 8179, 40534)
to the sequences contained in the HIV-DRD. The top 500 hits for
each sequence were analyzed for recombination profiles and
breakpoints using jpHMM and SCUEAL. Sequences with
identical subtype classifications and with a jpHMM breakpoint
that fell within the SCUEAL 95% confidence interval were
considered CRF50_A1D matches for further investigation.
The likely global origin of the parental subtype A1 and D strains
of CRF50 was investigated using global subtype alignments
containing subtype A1 or D sequences from every country in
the Los Alamos National HIV Database with a greater than 10%
representation of either subtype. These sequences were selected by
geographical region only and no further data was sought. One
alignment for each subtype was generated for partial gag, pol, and
env genes. The pol gene trees were supplemented with pure subtype
A and D sequences from the HIV-DRD. Approximate maximum
likelihood analysis was performed using FastTree 2.1 using a
GTR+CAT model (http://meta.microbesonline.org/fasttree/).
The emergence and distribution of identified CRF50_A1D
sequences in the UK was analyzed using time-scaled analyses
implemented in BEAST. The 72 putative CRF50_A1D sequences
were aligned with 8 reference A1 and D sequences from East
Africa, the 4 closest sequence matches in the NCBI database, and
4 subtype C sequences as an outgroup. A total of 36MCMC runs
of 16108 states were performed and combined for each analysis.
The GTR+C nucleotide model was used with a relaxed, log-
normal molecular clock and a Bayesian skyline coalescent with a
constant population distribution and 10 skyline groups. For
discrete phylogeographic analyses phylogeographic operators as
detailed in (http://beast.bio.ed.ac.uk/Discrete_Phylogeographic_
Analysis) were used with a resampled time-scaled tree as input. In
order to preserve patient anonymity, the locations of individual
clinics were not used as inputs into the phylogeographic analysis.
Instead, the geographic location for patients was determined using
aggregated center data which groups clinics together in approx-
imate locations; the central latitude/longitude point of each
aggregate was used as patient location. Following BEAST analysis,
phylogeographic trees were converted to .kml format and
visualized in Google Earth.
The A1/D recombinant structure was registered with the Los
Alamos National Database as CRF50_A1D. All six full-length
sequences were submitted to Genbank (accession numbers:
JN417236-JN417241); the reference sequence for CRF50_A1D
is JN417236.
Results
Identification and amplification of putative novel
recombinant sequences
Following screening of 55,556 HIV-1 pol gene sequences in the
HIV-DRD, sequences from eight subjects were identified that
appeared to share a novel recombinant structure. Stored plasma
samples from six of these eight subjects were retrieved from three
centers in the UK. The samples had been collected between 2000
and 2011 and stored at 280uC under routine conditions. The
HIV-1 RNA load measured at the time of sample collection
ranged from 9,148 to 500,000 copies/ml and the available sample
volumes ranged from 270 to 1500 ml. The optimal 20,000 HIV-1
RNA copies for sequencing were recovered from three of the six
samples; all six specimens, however, were successfully amplified at
lower than the 30% Poisson distribution set-point for single
genome amplification following limiting dilution.
Recombination analyses
RIP analysis of six specimens showed a putatively identical A1/
D structure with five of the six clinical isolates analyzed (33365,
8179, 40534, 11762, 12792); the sixth isolate (34567) showed a
complex A1/B/D structure (data not shown). jpHMM analysis
similarly identified five isolates with largely identical A1/D
structures (33365, 8179, 40543, 11762, 12792) and one isolate
with a complex A1/A2/D/B/U structure (34567) (Figure 1). The
Figure 1. jpHMM analysis of six recombinant HIV-1 sequences. Putative recombinant HIV-1 sequences were submitted to the online
implementation of jpHMM at the GOBICS server. The program used its own stored reference alignment and statistical algorithm to determine
subtype classifications, breakpoint locations and 95% confidence intervals. Breakpoint locations and confidence intervals are marked on each plot
and are equivalent to HXB2 numbering. In each plot, subtype A1 is represented in red, subtype A2 in coral (plot d only), subtype D in lavender, and
subtype B in blue (plot d only). Areas of subtype uncertainty are grey. Five specimens (a, b, c, e, and f) showed largely identical A1/D structures,
whereas one specimen (d) showed a complex A1/A2/D/B/U structure. a) Specimen 33365; b) Specimen 8179; c) Specimen 40534; d) Specimen 34567;
e) Specimen 11762; f) Specimen 12792.
doi:10.1371/journal.pone.0083337.g001
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breakpoint locations for the five A1/D specimens are summarized
in Table 1. Generally, the jpHMM breakpoint locations and
subtype classifications showed a good level of consistency among
the five A1/D specimens, and with the structure suggested by the
RIP screening. Two potential structural discrepancies were
suggested by jpHMM. With specimen 11762, the p2–p7 regions
of gag showed a lower degree of subtype A1 identity than observed
with the other four A1/D specimens; however, overlapping
confidence intervals indicated that the uncertainty was unlikely
to reflect a true structural difference. With specimens 33365 and
12792, two regions of env were designated as subtype D/uncertain
in the jpHMM plots; however bootscanning of these regions
confirmed the subtype D classification (Figure 2).
Breakpoints identified using bootscanning and informative sites
analyses were consistent with those identified using jpHMM. All
five A1/D specimens (33365, 8179, 40534, 11762, 12792) showed
identical bootscanning plots, with five subtype A1 regions and four
subtype D regions.
The jpHMM analysis of specimen 34567 further clarified the
recombinant structure of this complex isolate. Two clear regions
with the same structure as the five A1/D specimens were
identified, at the very beginning of gag, which had an identical
A1/D breakpoint (116268), and from the breakpoint in tat/rev
(5983623) to the end of the genome. This suggested that this
specimen resulted from a further recombination event between the
A1/D recombinant and a subtype B strain.
Maximum likelihood analyses
Maximum likelihood trees of putative non-recombinant frag-
ments drawn using PhyML with PAUP-defined parameters
showed that each fragment of each specimen clustered with the
pure subtype (A1 or D) indicated by the bootscanning analysis.
Results obtained with A1/D specimens 33365, 8179, and 40534,
and complex specimen 34567 are shown in Figure 3. The A1/D
structure was predominantly subtype A1 in pol and the accessory
genes; subtype D in env; and fairly evenly split between subtype A1
and D in gag. Three breakpoints were located in gag, one in pol, one
in tat/rev, and three in env, respectively. In gag, a breakpoint was
located at either end of p24, suggesting that the entire coding
region for the antigen was swapped in the recombination event.
Similarly, the third breakpoint was located at the junction of the
p7/p1 regions, suggesting that entire coding regions were swapped
in the recombination event. The distribution of subtypes in gag by
protein was A1 (p17, p2, p7) and D (p24, p1, p6).
The single D/A1 breakpoint in pol was located approximately
250 bp from the start of the protease; the remainder of the pol gene
was subtype A1, as were vif and vpr. The breakpoint located at
HXB2 6007 fell in the overlap of tat and rev; both of these genes
were A1/D mosaics. Vpu was solely subtype D. Although env was
largely subtype D, three of the hypervariable regions (V1–V3)
were subtype A1.
The maximum likelihood analysis confirmed that the A1/D
isolates clustered monophyletically across the entire genome
(Figure 3). The complex isolate 34567 clustered with the A1/D
isolates in 7/9 genomic regions; in 2/9 regions this specimen
clustered with subtype B reference sequences, confirming that this
specimen was a recombinant of the A1/D structure and a subtype
B infection (Figures 3 and 4).
Emergence and distribution of CRF50_A1D
Analysis of the UK HIV-DRD identified a further 67 sequences
showing a recombination profile that matched that of
CRF50_A1D. The global approximate maximum likelihood trees
were built using sequences from East Africa (Kenya, Tanzania,
Rwanda, Uganda, Burundi), Central Africa (DRC), Western
Africa (Cameroon), Eastern Europe (Latvia, Belarus, Georgia,
Russia) and the UK, due to the prevalence of subtypes A and D in
these regions. In the approximate maximum likelihood analysis of
global alignments of gag, pol and env gene subtype A and D
sequences the CRF50 sequences clustered monophyletically with
Figure 2. Bootscanning plots for five A1/D recombinants. Bootscanning plots from Simplot sliding window analysis using a window size of
400 bp, a step size of 20 bp and 100 bootscanning replicates. The y axis shows the percentage of permuted trees that the query sequence clustered
with the closest subtype match from the reference alignment. The x axis shows the nucleotide position of the sequence (not HXB2 numbering).
Subtype A is represented in red, subtype D in lavender, and subtype F (outgroup) in grey. All five specimens (33365, 8179, 40534, 11762, 12792)
showed identical bootscanning plots, with five subtype A1 regions and four subtype D regions. A) Specimen 33365; b) Specimen 8179; c) Specimen
40534; d) Specimen 11762; e) Specimen 12792.
doi:10.1371/journal.pone.0083337.g002
Table 1. jpHMM-assigned breakpoint locations (with 95% confidence intervals) for five HIV-1 A1/D recombinant sequencesa.
Break point Study number Gene Region
33365 8179 40534 11762 12792
1 1162 (1154–1170) 1159 (1147–1171) 1167 (1148–1186) 1177 (1154–1200) 1156 (1141–1171) gag p24
2 1843 (1809–1877) 1844 (1809–1879) 1844 (1809–1879) 1958* (1811–2105) 1828 (1809–1847) gag p24
3 2089 (2047–2131) 2078 (2046–2110) 2078 (2046–2110) 2078 (2046–2110) 2056 (2002–2110) gag p1
4 2489 (2463–2515) 2489 (2465–2515) 2489 (2465–2515) 2487 (2475–2499) 2598{ (2463–2733) pol PR
5 5981 (5951–6011) 5979 (5953–6005) 5976 (5951–6001) 5985 (5973–5997) 5998 (5989–6007) tat/rev
6 6551 (6543–6559) 6551 (6543–6559) 6551 (6543–6559) 6551 (6539–6563) 6551 (6543–6559) env gp120
7 7247 (7234–7260) 7246 (7231–7261) 7249 (7232–7266) 7483 (7471–7495) 7214 (7171–7257) env gp120
8 8679 (8664–8694) 8672 (8651–8693) 8679 (8663–8695) 8674 (8662–8686) 8678 (8663–8693) env gp41
aBreakpoint locations as determined by jpHMM with HXB2 numbering. The breakpoint locations are generally consistent across the five specimens, indicating that the
same A1/D recombinant structure is shared.
*This corresponds to a region of subtype D uncertainty;
{This corresponds to a region of subtype A uncertainty; refer to Figure 1. PR = Protease.
doi:10.1371/journal.pone.0083337.t001
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the East African sequences in both the subtype A and subtype D
trees (data not shown). No clustering was observed with subtype
A1 or D sequences from the UK. This suggested that CRF0_A1D
probably originated in East Africa and was possibly introduced to
the UK as a recombinant, rather than emerging from subtype A1
and D strains circulating in the UK.
Figure 3. Recombinant map of CRF50_A1D and maximum likelihood phylogenetic trees of non-recombinant fragments. Maximum
likelihood trees of putative non-recombinant fragments from specimens 33365, 8179, 40534 and 34567 drawn using PhyML with PAUP-defined
parameters. HIV-1 subtypes used for analysis were A–D, F, G, H, J, K. Numbers indicate bootstrapping support from 1000 replicates (excepting slice 5;
100 replicates). 70% bootstrap support and monophyletic clustering were the criteria for subtype classification. The recombinant map was drawn
using the RDT program at Los Alamos. Component subtype fragments are labeled 1–9 on the genome map, corresponding with numbered
phylogenetic trees. The genomic regions in which the URF specimen 34567 did not cluster with the CRF50_A1D specimens are indicated in the
appropriate trees.
doi:10.1371/journal.pone.0083337.g003
Figure 4. Confirmed structure of the complex recombinant. The confirmed structure of the complex A1/B/D/U recombinant specimen 34567
following maximum likelihood analysis with the CRF50_A1D specimens. CRF50_A1D regions are shown in green and subtype B regions are shown in
blue.
doi:10.1371/journal.pone.0083337.g004
Identification of HIV-1 CRF50_A1D
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e83337
Identification of HIV-1 CRF50_A1D
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e83337
Time-scaled analysis dated the emergence of CRF50_A1D in
the UK to 1992 [95% highest posterior density (HPD) 1966–2007;
posterior probability 0.9933] (Figure 5). Phylogeographic analysis
showed probable emergence in northwest England followed by
spread to London and southeast England, with further, limited
transmission events in southwest and northeast England and
Scotland. Demographic information was available for 51/72
patients infected with CRF50_A1D. Of these, 45 (88.2%) were
MSM, 3 (5.9%) were heterosexual males, and 2 (3.9%) were IDUs.
Analysis including the CRF50/B/U unique recombinant form
(URF) sequence showed a median divergence date of 2000,
indicating an onward recombination event between CRF50_A1D
and a subtype B strain. The CRF50_A1D/B/U sequence came
from an MSM.
Discussion
The HIV epidemic in MSM in the UK continues to diversify,
creating opportunities for the emergence of novel recombinant
forms. By scanning a large national sequence repository, we
identified 72 patients who all appeared to be infected with the
same novel A1/D recombinant. Near full-length SGS of plasma
HIV-1 RNA was performed to characterize the structure of the
recombinant. Five patients were found to carry the same A1/D
recombinant, which was classified as CRF50_A1D. Based on the
recombinant profile, we conclude that CRF50_A1D is the subtype
A recombinant that Gifford et al hypothesized was circulating
among MSM in 2007 [6]. It should be noted that some
recombination breakpoints were not identical among the five
CRF50_A1D isolates in the jpHMM plots. However, the
confidence intervals of the identity estimations and the subsequent
analyses indicated that the uncertainties were unlikely to reflect a
true alternative recombinant structure. We also found evidence of
further genetic evolution of CRF50_A1D through recombination
with subtype B, which is the predominant HIV-1 subtype
circulating among MSM in the UK. This complex URF was
classified as CRF50_A1D/B/U. Crucially, the estimated emer-
gence date of 1992 was both prior to the introduction of highly
active antiretroviral therapy and during a period when HIV
infections were spreading exponentially in African countries,
creating ideal conditions for the creation of novel HIV recombi-
nants which could move into the wider epidemic.
We found a relatively low number of patients infected with this
strain within a database that at the time of screening contained
55,556 sequences from 43,002 patients. This relatively modest
spread could reflect fitness properties of the CRF. We detected an
unusual structure of the env gene in this recombinant, in which
three out of the five hypervariable regions belonged to subtype A1,
whereas the remaining two regions belonged to subtype D.
Available data indicate that recombination events in env tend to
include either the entire gene or at least the entirety of gp120, and
this has been related to the functional impact of this protein on
viral fitness [15].
We found that CRF50_A1D was related to A1 and D strains of
East African origin. A1/D recombinants detected in East Africa
have been associated with a fast disease progression, which may
limit the number of infections in the community [16–19]. It should
be noted however that in a sub-analysis, the CD4 cell count slopes
before starting ART were similar in MSM infected with subtype B
or CRF50_A1D (data not shown). These considerations indicate
that CRF50_A1D has potentially interesting phenotypic proper-
ties, which would bear further investigation. Further studies are
required to indicate whether there is an influence on clinical
outcomes or treatment responses.
There are limitations to this study. Our phylogeographic
approach dated the emergence of CRF50_A1D in the UK to
mid-1992. This study had a limited number of sequences with
which to draw this inference. The prevalence of CRF50_A1D was
low in the dataset (72/43,002 or 0.17%) with no evidence for rate
increase over time. While the UK-DRB comprehensively collects
pol gene sequences from patients undergoing drug resistance in
routine care in the UK, not all HIV centers contribute to the
dataset. Furthermore, the database contains only protease and
reverse transcriptase sequences and there are similarity between
subtype B and subtype D in these genetic regions. Thus it may be
proposed that the 72 CRF50_A1D infections identified represent
an underestimate. This in turn may potentially bias the estimated
date of emergence. Evolutionary analysis of the individual gene
using the available full-length sequences and reconstruction of the
ancestral subtype A1 and D strains may yield a more precise
elucidation of the emergence date and help to determine whether
single or multiple introductions occurred in the UK. Furthermore,
given that the majority of 72 individuals infected with
CRF50_A1D had only partial pol sequences available for analysis,
it may be postulated that some of these cases may have shown a
more complex viral genomic structure if full-length genome
analysis had been performed.
The study of novel HIV variants such as CRF50_A1D and the
URF CRF50/B/U provides a tool for studying transmission
networks and interactions between populations and risk groups,
thus producing valuable epidemiological insights [20,21]. Al-
though in the early years of the HIV epidemic in Western Europe
it was rare to find non-B infections in MSM [22], more recent data
indicate that non-B infections are not only increasingly important,
but are being transmitted indigenously among this population
[23]. The use of molecular epidemiological techniques to map
these variants can add to our understanding of data gathered using
traditional epidemiological means and provides valuable insights
into the dynamics of the HIV epidemic that can be used to guide
control strategies.
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